Skip to content
yes i take peptides.
Library/For Long/Vesugen
RUO · Research Use Only⚠ Russian-only data+2 more

Vesugen

A three-amino-acid peptide from the Khavinson 'short peptide bioregulator' family. We read all 27 studies. The protocol is below.

Updated 03 May 2026Read 7 minEvidence ●○○○○Citations 27
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts Vesugen on your decision board.

The Vesugen Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 27 cited studies.

Status
Research-only
Class
Russian-only data
Evidence
1/ 5●○○○○
Independently replicated trials
$19 ↓
Khavinson group papers
$19 ↓
Western Phase 2/3 trials
$19 ↓
⚠ Russian-only data
Read this if
  • you're cycling Khavinson bioregulators and vesugen is your vascular-tissue pick this season
  • you have borderline lipids, you're already on a statin, and you want the next adjunct
  • you're 50+ and reading Russian-translation papers because the Western literature won't touch this stuff
Skip this if
  • **you're on an antihypertensive (ACE-I, ARB, beta-blocker, calcium-channel-blocker, thiazide)** — the Khavinson group's own publications describe Vesugen *as an adjunct to antihypertensives that allowed lower conventional drug doses*; the implication you don't see in the marketing is that the **combined effect is additive — and additive hypotension is a real failure mode** without your prescriber tracking the home-cuff readings
  • you want randomized Western trial data — it doesn't exist
  • you have active cardiovascular disease and need a drug that's actually been tested in a real CVOT
  • you're not okay with cardiovascular-adjacent supplementation outside a cardiologist's plan
The 4 ways you can buy Vesugen
Brand
✗
Not available
No FDA-approved vesugen exists.
Compounded 503A
✓
Off-label
$100–$220/mo where sold
Mid–high. Few compounders carry; the Khavinson-only evidence base means clinical legitimacy is weak.
RUO (research-only)
✓
Sold 'for research only'
$30–$120/mo
The dominant supply; small tripeptide is cheap to synthesize.
Gray market
✓
Unregulated overseas import
Varies — not on user's vendor list
Available via overseas raws (cheap to synthesize) but vesugen has limited demand vs Epitalon, so s…
Click any lane for the full Sourcing breakdown.
First 90 days · Vesugen
Weeks 1–2
Nothing perceptible. Longevity peptides are not 'feel something' molecules. If a vendor says you'll notice an effect this fast, they're selling you on placebo.
Weeks 4–8
Possibly subtle shifts in biomarkers (inflammation, sleep, recovery). Subjective changes in this window are usually placebo and confounded with whatever else you changed.
Week 12 — decide
Bloodwork or biomarker check. If the protocol can't be defended on a labeled change at 12 weeks, it can't be defended on hope.
Quit if
  • Any unusual symptoms — especially the cancer-mechanism flag for angiogenic peptides.
  • 12 weeks of continuous use with no objective biomarker support to keep going.
  • Tolerance signal (the protocol needs escalating doses to feel the same).
Identity

What it is.

Vesugen is a tripeptide (Lys-Glu-Asp) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the Khavinson family of short "bioregulator" peptides, with each member supposedly targeting a specific tissue. Vesugen is the vascular-endothelium member.

The pitch: Vesugen normalizes endothelial gene expression, supports vascular tone, and reduces age-related vascular stiffness. The marketed effects center on cardiovascular aging, blood-pressure stability, and microcirculation.

It is sold strictly as a research chemical (RUO) in the US and Europe. There is no version. In Russia, related Khavinson peptides have been used in clinical settings under a regulatory framework that does not match FDA approval.

Dosing in the Khavinson tradition is short courses — typically 10–20 days, repeated seasonally — rather than continuous daily use.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Vesugen actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the Vesugen report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the Vesugen report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
Independently replicated trials
$19 ↓
Khavinson group papers
$19 ↓
Western Phase 2/3 trials
$19 ↓
Half-life
$19 ↓
Antihypertensive interaction
$19 ↓
Stack with Epitalon
$19 ↓
WADA status
$19 ↓
Long-term safety data
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the Vesugen report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 27 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Vesugen report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 27 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the Vesugen report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the Vesugen report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Meshchaninov VN, et al. [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. Advances in gerontology = Uspekhi gerontologii. 2015;28(1):62-7. PMID: 26390612.
  2. 02Khavinson VKh, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of experimental biology and medicine. 2012;153(1):148-51. PMID: 22808515.
  3. 03Khavinson VKh, et al. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Advances in gerontology = Uspekhi gerontologii. 2014;27(1):108-14. PMID: 25051766.
  4. 04Linkova NS, et al. Peptidegic stimulation of differentiation of pineal immune cells. Bulletin of experimental biology and medicine. 2011;152(1):124-7. PMID: 22803057.
  5. 05Kozina LS. [Investigation of antihypoxic properties of short peptides]. Advances in gerontology = Uspekhi gerontologii. 2008;21(1):61-7. PMID: 18546825.
+Show all 27 citations
  1. 06Kozina LS, et al. [Biological activity of regulatory peptides in model experiments in vitro]. Advances in gerontology = Uspekhi gerontologii. 2008;21(1):68-73. PMID: 18546826.
  2. 07Khavinson VK, et al. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Bulletin of experimental biology and medicine. 2021;171(2):190-193. PMID: 34173097.
  3. 08Kraskovskaya N, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International journal of molecular sciences. 2024;25(21). PMID: 39518916.
  4. 09Caputi S, et al. Effect of short peptides on neuronal differentiation of stem cells. International journal of immunopathology and pharmacology. 2019;33:2058738419828613. PMID: 30791821.
  5. 10Khavinson VKh, et al. Molecular aspects of anti-atherosclerotic effects of short peptides. Bulletin of experimental biology and medicine. 2014;158(1):159-63. PMID: 25408528.
  6. 11Khavinson VKh, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of experimental biology and medicine. 2014;157(1):77-80. PMID: 24909721.
  7. 12Lin'kova NS, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bulletin of experimental biology and medicine. 2016;161(1):175-8. PMID: 27259496.
  8. 13Ashapkin V, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular biology reports. 2020;47(6):4323-4329. PMID: 32399807.
  9. 14Rytömaa T, et al. Spontaneous death of rat chloroleukaemia cells induced by an endogenous growth inhibitor. Cell proliferation. 2018;51(1). PMID: 29226462.
  10. 15Chalisova NI, et al. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bulletin of experimental biology and medicine. 2012;153(4):569-72. PMID: 22977872.
  11. 16Khavinson VKh, et al. Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture. Bulletin of experimental biology and medicine. 2011;152(1):138-41. PMID: 22803060.
  12. 17Voicekhovskaya MA, et al. Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats. Bulletin of experimental biology and medicine. 2012;152(3):357-9. PMID: 22803085.
  13. 18Myakotnykh VS, et al. [Comparative analysis of different methods of geroprotective]. Advances in gerontology = Uspekhi gerontologii. 2016;29(4):594-601. PMID: 28539017.
  14. 19Jing J. Synthesis and activity of a cyclo-heptapeptide containing Lys-Gly-Asp-sequence as a novel anti-platelet agent. Bioorganicheskaia khimiia. 2013;39(5):547-51. PMID: 25702411.
  15. 20Kozlov KL, et al. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Advances in gerontology = Uspekhi gerontologii. 2016;29(4):646-650. PMID: 28539025.
  16. 21Bashkireva AS, et al. [Assessment of work ability index in evaluation of small peptides geroprotective effect]. Advances in gerontology = Uspekhi gerontologii. 2015;28(3):510-512. PMID: 28509489.
  17. 22Bashkireva AS, et al. [The peptide correction of neurotic disorders among professional truck-drivers]. Advances in gerontology = Uspekhi gerontologii. 2012;25(4):718-28. PMID: 23734521.
  18. 23Iarilin AA, et al. [Changes of thymocyte differentiation, proliferation and apoptosis induced by syntetic peptides]. Morfologiia (Saint Petersburg, Russia). 2011;140(4):23-6. PMID: 22171428.
  19. 24Chalisova NI, et al. Protective effect of tripeptide in the presence of cyclophosphamide on the growth of cultured lymphoid tissue from rats of different age. Bulletin of experimental biology and medicine. 2008;145(6):748-50. PMID: 19110568.
  20. 25Kitachev KV, et al. [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Advances in gerontology = Uspekhi gerontologii. 2014;27(1):156-9. PMID: 25051774.
  21. 26Ryzhak AP, et al. [Peptidergic regulation of the pancreas function in the experimental model of rats with accelerated aging]. Advances in gerontology = Uspekhi gerontologii. 2008;21(2):240-5. PMID: 18942368.
  22. 27Trofimov AV. [Tripeptide restorates structure of duodenum at accelerated aging]. Advances in gerontology = Uspekhi gerontologii. 2011;24(3):511-4. PMID: 22184986.
The Vesugen Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 27 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →